Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

1672803

USP

Transplatin

United States Pharmacopeia (USP) Reference Standard

Synonym(s):

trans-Platinum(II)diammine dichloride, trans-Diamminedichloroplatinum(II), trans-Dichlorodiammineplatinum(II)

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Linear Formula:
Pt(NH3)2Cl2
CAS Number:
14913-33-8
Molecular Weight:
300.05
MDL number:
MFCD00011623
UNSPSC Code:
41116107
PubChem Substance ID:
329751363
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

cisplatin

manufacturer/tradename

USP

mp

340 °C (dec.) (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

N.N.Cl[Pt]Cl

InChI

1S/2ClH.2H3N.Pt/h2*1H;2*1H3;/q;;;;+2/p-2

InChI key

LXZZYRPGZAFOLE-UHFFFAOYSA-L

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

C2210000

Cisplatin, European Pharmacopoeia (EP) Reference Standard

Y0001019

Cisplatin impurity B, European Pharmacopoeia (EP) Reference Standard

Y0001018

Cisplatin impurity A, European Pharmacopoeia (EP) Reference Standard

1551300

Potassium Trichloroammineplatinate, United States Pharmacopeia (USP) Reference Standard

1134357

Cisplatin, United States Pharmacopeia (USP) Reference Standard

PHR1624

Cisplatin, Pharmaceutical Secondary Standard; Certified Reference Material

BP809

Cisplatin, British Pharmacopoeia (BP) Reference Standard

BP510

Potassium trichloroammineplatinate, British Pharmacopoeia (BP) Reference Standard

BP544

Transplatin, British Pharmacopoeia (BP) Reference Standard

Pictograms

Health hazardCorrosion
GHS08,GHS05

Signal Word

Danger

Hazard Statements

H317,H318,H334

Hazard Classifications

Eye Dam. 1 - Resp. Sens. 1 - Skin Sens. 1

Storage Class Code

13 - Non Combustible Solids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Vicente Fresquet et al.
Blood, 123(26), 4111-4119 (2014-05-03)
Acquired resistance to targeted drugs is emerging as an obstacle to successful cancer treatment. Recently, a BCL2-selective BH3 mimetic termed ABT-199 showed promising therapeutic results in BCL2-dependent tumors. Based on its high affinity for BCL2, we studied potential mechanisms conferring
Yuniardini S Wimardhani et al.
Journal of oral science, 56(2), 119-126 (2014-06-17)
Chitosan, a multipurpose biomaterial, has been shown to exert effects against several types of cancer including oral cancer. However, the mechanisms underlying the anticancer activities of chitosan on oral squamous cell carcinoma (SCC) cells remain largely unknown. The present study
Michelle X Liu et al.
Oncotarget, 5(4), 944-958 (2014-03-25)
Epithelial ovarian cancer is a highly lethal and aggressive gynecological malignancy. The high mortality rate is due in part to the fact that many advanced cancer patients become refractory to current chemotherapeutic agents, leading to tumor recurrence and death. However
Wei Qian et al.
Oncotarget, 5(12), 4180-4194 (2014-06-24)
Overcoming platinum drug resistance represents a major clinical challenge in cancer treatment. We discovered a novel drug combination using cisplatin and a class of thioquinazolinone derivatives including mdivi-1 (mitochondrial division inhibitor-1), that induces synergistic apoptosis in platinum resistant tumor cells
Benjamin J Solomon et al.
The New England journal of medicine, 371(23), 2167-2177 (2014-12-04)
The efficacy of the ALK inhibitor crizotinib as compared with standard chemotherapy as first-line treatment for advanced ALK-positive non-small-cell lung cancer (NSCLC) is unknown. We conducted an open-label, phase 3 trial comparing crizotinib with chemotherapy in 343 patients with advanced
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service